$LQDA
Liquidia Corp

2024 Q3 Form 10-Q Financial Statement

#000155837024011206 Filed on August 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $4.448M $3.659M
YoY Change 20.94% -23.55%
Cost Of Revenue $1.565M $1.493M
YoY Change 174.56% 122.5%
Gross Profit $2.883M $2.166M
YoY Change -7.24% -47.36%
Gross Profit Margin 64.82% 59.2%
Selling, General & Admin $20.18M $19.94M
YoY Change 91.12% 115.72%
% of Gross Profit 700.03% 920.73%
Research & Development $11.89M $9.420M
YoY Change 59.81% -46.76%
% of Gross Profit 412.42% 434.9%
Depreciation & Amortization $610.0K $580.0K
YoY Change 19.61% -1.53%
% of Gross Profit 21.16% 26.78%
Operating Expenses $11.89M $9.420M
YoY Change 59.81% -46.76%
Operating Profit -$29.19M -$27.20M
YoY Change 96.02% 19.15%
Interest Expense $2.996M $2.600M
YoY Change 70.13% 82.33%
% of Operating Profit
Other Income/Expense, Net $6.034M -$745.0K
YoY Change -771.19% 7.66%
Pretax Income -$23.16M -$27.94M
YoY Change 46.64% 18.82%
Income Tax
% Of Pretax Income
Net Earnings -$23.16M -$27.94M
YoY Change 46.64% 18.82%
Net Earnings / Revenue -520.57% -763.65%
Basic Earnings Per Share -$0.30 -$0.37
Diluted Earnings Per Share -$0.30 -$0.37
COMMON SHARES
Basic Shares Outstanding 76.79M 76.38M
Diluted Shares Outstanding 78.32M 76.44M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $204.4M $133.1M
YoY Change 168.2% 50.91%
Cash & Equivalents $204.4M $133.1M
Short-Term Investments
Other Short-Term Assets $5.604M $3.707M
YoY Change 64.82% 516.81%
Inventory $38.00K $7.212M
Prepaid Expenses
Receivables $4.202M $3.249M
Other Receivables $0.00 $0.00
Total Short-Term Assets $214.2M $147.3M
YoY Change 158.15% 58.53%
LONG-TERM ASSETS
Property, Plant & Equipment $7.784M $6.387M
YoY Change 76.91% 53.13%
Goodwill $3.903M $3.903M
YoY Change 0.0% 0.0%
Intangibles $3.219M $3.300M
YoY Change -7.79% -7.15%
Long-Term Investments
YoY Change
Other Assets $7.758M $15.04M
YoY Change -48.62% -0.82%
Total Long-Term Assets $38.67M $30.10M
YoY Change 34.94% 4.86%
TOTAL ASSETS
Total Short-Term Assets $214.2M $147.3M
Total Long-Term Assets $38.67M $30.10M
Total Assets $252.9M $177.4M
YoY Change 126.52% 45.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.298M $5.741M
YoY Change 26.82% 199.32%
Accrued Expenses $18.29M $14.33M
YoY Change 140.63% -8.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $13.25M $4.154M
YoY Change 390.81% 125.15%
Total Short-Term Liabilities $33.84M $24.22M
YoY Change 178.36% 24.24%
LONG-TERM LIABILITIES
Long-Term Debt $99.89M $81.76M
YoY Change 136.71% 156.18%
Other Long-Term Liabilities $8.638M $8.655M
YoY Change -7.12% -9.16%
Total Long-Term Liabilities $108.5M $90.42M
YoY Change 110.74% 118.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.84M $24.22M
Total Long-Term Liabilities $108.5M $90.42M
Total Liabilities $142.4M $114.6M
YoY Change 123.73% 88.12%
SHAREHOLDERS EQUITY
Retained Earnings -$521.1M -$498.0M
YoY Change 29.76% 29.05%
Common Stock $85.00K $76.00K
YoY Change 30.77% 16.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $110.5M $62.72M
YoY Change
Total Liabilities & Shareholders Equity $252.9M $177.4M
YoY Change 126.52% 45.86%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$23.16M -$27.94M
YoY Change 46.64% 18.82%
Depreciation, Depletion And Amortization $610.0K $580.0K
YoY Change 19.61% -1.53%
Cash From Operating Activities -$25.08M -$22.66M
YoY Change 116.97% 307.28%
INVESTING ACTIVITIES
Capital Expenditures $1.747M $1.290M
YoY Change -83.31% 430.86%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$1.747M -$1.290M
YoY Change -83.31% 430.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 98.10M -814.0K
YoY Change 874.22% 99.02%
NET CHANGE
Cash From Operating Activities -25.08M -22.66M
Cash From Investing Activities -1.747M -1.290M
Cash From Financing Activities 98.10M -814.0K
Net Change In Cash 71.28M -24.76M
YoY Change -695.94% 298.41%
FREE CASH FLOW
Cash From Operating Activities -$25.08M -$22.66M
Capital Expenditures $1.747M $1.290M
Free Cash Flow -$26.83M -$23.95M
YoY Change 21.78% 312.45%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001819576
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76414548
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
68629575
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39724
dei Entity Registrant Name
EntityRegistrantName
LIQUIDIA CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1710962
dei Entity Address Address Line1
EntityAddressAddressLine1
419 Davis Drive, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
Morrisville
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27560
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
328-4400
dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
LQDA
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76793694
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133093000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83679000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3249000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4061000
CY2024Q2 us-gaap Inventory Gross
InventoryGross
7212000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3707000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2159000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
147261000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
89899000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6387000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4480000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1471000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1704000
CY2024Q2 lqda Indemnification Asset Related Party
IndemnificationAssetRelatedParty
7194000
CY2023Q4 lqda Indemnification Asset Related Party
IndemnificationAssetRelatedParty
6707000
CY2024Q2 lqda Business Combination Contract Acquisition Costs Net
BusinessCombinationContractAcquisitionCostsNet
7621000
CY2023Q4 lqda Business Combination Contract Acquisition Costs Net
BusinessCombinationContractAcquisitionCostsNet
7922000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3300000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3430000
CY2024Q2 us-gaap Goodwill
Goodwill
3903000
CY2023Q4 us-gaap Goodwill
Goodwill
3903000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
224000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
287000
CY2024Q2 us-gaap Assets
Assets
177361000
CY2023Q4 us-gaap Assets
Assets
118332000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
5741000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1396000
CY2024Q2 lqda Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
13100000
CY2023Q4 lqda Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
13400000
CY2024Q2 lqda Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
4154000
CY2023Q4 lqda Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
2615000
CY2024Q2 lqda Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1225000
CY2023Q4 lqda Operating And Finance Lease Liability Current
OperatingAndFinanceLeaseLiabilityCurrent
1139000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
24220000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18550000
CY2024Q2 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
6929000
CY2023Q4 us-gaap Litigation Reserve Noncurrent
LitigationReserveNoncurrent
6707000
CY2024Q2 lqda Revenue Interest Financing Payable Noncurrent
RevenueInterestFinancingPayableNoncurrent
81764000
CY2023Q4 lqda Revenue Interest Financing Payable Noncurrent
RevenueInterestFinancingPayableNoncurrent
43418000
CY2024Q2 lqda Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
1726000
CY2023Q4 lqda Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
2364000
CY2024Q2 us-gaap Liabilities
Liabilities
114639000
CY2023Q4 us-gaap Liabilities
Liabilities
71039000
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76414548
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
68629575
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
76000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
69000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
560614000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
476322000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-497968000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-429098000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
62722000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
47293000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
177361000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
118332000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3659000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4786000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6631000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
9279000
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1493000
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
671000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2960000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1325000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9420000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17695000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19477000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22973000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19943000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9245000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
40192000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17038000
CY2024Q2 us-gaap Costs And Expenses
CostsAndExpenses
30856000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
27611000
us-gaap Costs And Expenses
CostsAndExpenses
62629000
us-gaap Costs And Expenses
CostsAndExpenses
41336000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-27197000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-22825000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55998000
us-gaap Operating Income Loss
OperatingIncomeLoss
-32057000
CY2024Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1855000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
734000
us-gaap Investment Income Interest
InvestmentIncomeInterest
3735000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1656000
CY2024Q2 us-gaap Interest Expense
InterestExpense
2600000
CY2023Q2 us-gaap Interest Expense
InterestExpense
1426000
us-gaap Interest Expense
InterestExpense
5124000
us-gaap Interest Expense
InterestExpense
2550000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11483000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2311000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-745000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-692000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12872000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3205000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-27942000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23517000
us-gaap Net Income Loss
NetIncomeLoss
-68870000
us-gaap Net Income Loss
NetIncomeLoss
-35262000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.36
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.36
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.91
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.91
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76435831
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76435831
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64788482
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64788482
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75914869
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75914869
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64722818
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64722818
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
47293000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
99000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
404000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
74868000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4524000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-40928000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
86260000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4372000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-27942000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
62722000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
90422000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
79000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
335000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2552000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-11745000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
81643000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
32000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2499000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-23517000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
60657000
us-gaap Profit Loss
ProfitLoss
-68870000
us-gaap Profit Loss
ProfitLoss
-35262000
lqda Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
10000000
us-gaap Share Based Compensation
ShareBasedCompensation
8896000
us-gaap Share Based Compensation
ShareBasedCompensation
5051000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1069000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1158000
lqda Noncash Portion Of Lease Expense
NoncashPortionOfLeaseExpense
233000
lqda Noncash Portion Of Lease Expense
NoncashPortionOfLeaseExpense
187000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11483000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2311000
lqda Accretion And Non Cash Interest Expense
AccretionAndNonCashInterestExpense
5119000
lqda Accretion And Non Cash Interest Expense
AccretionAndNonCashInterestExpense
2376000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-812000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-922000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7212000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1548000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-760000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-63000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-47000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3224000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-380000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-300000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-755000
lqda Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-499000
lqda Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-434000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-47527000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14021000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1914000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
609000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1914000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-607000
lqda Proceeds From Revenue Interest Financing Net
ProceedsFromRevenueInterestFinancingNet
24975000
lqda Proceeds From Revenue Interest Financing Net
ProceedsFromRevenueInterestFinancingNet
31814000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
20000000
us-gaap Repayments Of Debt
RepaymentsOfDebt
2190000
lqda Payments On Revenue Interest Financing Liability
PaymentsOnRevenueInterestFinancingLiability
1692000
lqda Payments On Revenue Interest Financing Liability
PaymentsOnRevenueInterestFinancingLiability
500000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
53000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
130000
us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
222000
us-gaap Loss Contingency Receivable Proceeds
LossContingencyReceivableProceeds
101000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
74868000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
535000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
446000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98855000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
9541000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
49414000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5087000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
83679000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
93283000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
133093000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
88196000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
360000
lqda Operating Lease Liabilities Cash Paid
OperatingLeaseLiabilitiesCashPaid
655000
lqda Operating Lease Liabilities Cash Paid
OperatingLeaseLiabilitiesCashPaid
637000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
634000
lqda Increase In Indemnification Asset Through Accounts Payable
IncreaseInIndemnificationAssetThroughAccountsPayable
487000
lqda Increase In Indemnification Asset Through Accounts Payable
IncreaseInIndemnificationAssetThroughAccountsPayable
101000
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1. Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Description of the Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company focused on the development, manufacture, and commercialization of products that address unmet patient needs, with current focus directed towards rare cardiopulmonary diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”). We operate through our wholly owned operating subsidiaries, Liquidia Technologies, Inc. (“Liquidia Technologies”) and Liquidia PAH, LLC (“Liquidia PAH”), formerly known as RareGen, LLC (“RareGen”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently generate revenue pursuant to a promotion agreement between Liquidia PAH and Sandoz Inc. (“Sandoz”), dated as of August 1, 2018, as amended (the “Promotion Agreement”), sharing profit derived from the sale of Sandoz’s substitutable generic treprostinil injection (“Treprostinil Injection”) in the United States. Liquidia PAH has the exclusive rights to conduct commercial activities to encourage the appropriate use of Treprostinil Injection. We employ a targeted sales force calling on physicians and hospital pharmacies involved in the treatment of PAH and PH-ILD in the United States, as well as key stakeholders involved in the distribution and reimbursement of medicines to treat these patients. We established our commercial presence in the field to support Treprostinil Injection and have since expanded our presence to support the potential launch of YUTREPIA upon final approval, further validating our reputation as a company committed to supporting PAH and PH-ILD patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We conduct research, development and manufacturing of novel products by applying our subject matter expertise in cardiopulmonary diseases and our proprietary PRINT® technology, a particle engineering platform, to enable precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Through development of our own products and research with third parties, we have experience applying PRINT across multiple routes of administration and drug payloads including inhaled therapies, vaccines, biologics, nucleic acids and ophthalmic implants, among others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, low effort dry-powder inhaler (“DPI”) and by achieving higher dose levels than the labeled doses of current inhaled therapies. In November 2021, the United States Food and Drug Administration (“FDA”) tentatively approved our New Drug Application (“NDA”) for YUTREPIA for the treatment of PAH. In July 2023, we filed an amendment to our NDA to add PH-ILD to the label for YUTREPIA. We are currently awaiting final action by the FDA with respect to our NDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer, which we licensed from Pharmosa. L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD with a planned pivotal study for the treatment of PH-ILD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are subject to risks and uncertainties common to companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, dependence on third parties and key personnel, protection of proprietary technology, compliance with government regulations, and the ability to secure additional capital to fund operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The current global macro-economic environment is volatile, which may result in supply chain constraints and elevated rates of inflation. In addition, we operate in a dynamic and highly competitive industry and believe that changes in any of the following areas could have a material adverse effect on our future financial position, results of operations, or cash flows: the ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval, market acceptance and third-party payor coverage for our products; development of sales channels; certain strategic relationships; litigation or claims against us, including claims related to intellectual property, product, regulatory, or other matters; and our ability to attract and retain employees necessary to support our growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Product candidates we develop require approval from the FDA and/or other international regulatory agencies prior to commercial sales. There can be no assurance that our product candidates will receive the necessary approvals or, if we do, the indications for which our products will be approved. If we are denied approval, approval is delayed, approval is for less than all of the indications we are seeking, or we are unable to maintain approval, it could have a material adverse impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We rely on single source manufacturers and suppliers for the supply of our product candidates, adding to the manufacturing risks we face. In the event of any failure by a supplier, we could be left without backup facilities. Any disruption from these manufacturers or suppliers could have a negative impact on our business, financial position and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Liquidity and Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In accordance with Accounting Standards Update (“ASU”) 2014-15, <i style="font-style:italic;">Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40)</i>, we have evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. We have financed our growth and operations through a combination of funds generated from revenues, the issuance of convertible preferred stock and common stock, bank borrowings, bank borrowings with warrants, the issuance of convertible notes and warrants, and revenue interest financing. Since inception, we have incurred recurring losses, including a net loss of $68.9 million for the six months ended June 30, 2024. As of June 30, 2024, we had an accumulated deficit of $498.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through clinical trials, seek regulatory approval of such product candidates and pursue commercialization of any approved product candidates. These efforts require significant amounts of capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if our development efforts are successful, it is uncertain when, if ever, we will realize significant revenue from product sales. Additionally, the Revenue Interest Financing Agreement with HealthCare Royalty Partners IV, L.P. (“HCR”) dated January 9, 2023, as amended (the “RIFA”) contains fixed quarterly payments and minimum cash covenants that require us to maintain cash and cash equivalents in an amount at least equal to $7.5 million during the calendar year beginning on January 1, 2024 and at least equal to $15.0 million for the remainder of the payment term after the calendar year ended December 31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our future funding requirements will be heavily determined by the timing of the potential commercialization of YUTREPIA and the resources needed to support development of our product candidates. Based on our current plans, we expect that we will require additional capital to fund operations as well as to pursue in-licenses or acquisitions of other product candidates. If we are unable to obtain additional funding, we could be required to delay, reduce, or eliminate research and development programs, product portfolio expansion, or future commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Based on current operating plans and excluding any contribution from potential YUTREPIA product sales or external financing, we will not have sufficient cash and cash equivalents to fund operating expenses and capital requirements and meet our minimum cash covenants beyond one year from the issuance of these condensed consolidated financial statements, and therefore, the Company has concluded that there is substantial doubt about its ability to continue as a going concern. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect.</p>
us-gaap Net Income Loss
NetIncomeLoss
-68900000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-498000000.0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the period. These estimates are based on historical experience and various other assumptions believed to be reasonable under the circumstances. We evaluate our estimates on an ongoing basis, including those related to the valuation of stock-based awards, certain accruals, the revenue interest financing payable, and intangible and contract acquisition cost amortization, and make changes to the estimates and related disclosures as our experience develops or new information becomes known. Actual results will most likely differ from those estimates.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q2 us-gaap Inventory Gross
InventoryGross
7200000
CY2023Q4 us-gaap Inventory Gross
InventoryGross
0
CY2024Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2024Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12959258
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11730746
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12981346
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11587457
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
2676000
CY2024Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
4536000
CY2024Q2 us-gaap Inventory Gross
InventoryGross
7212000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
7200000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
21981000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19794000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15594000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
15314000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6387000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4480000
CY2024Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
400000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
600000
CY2024Q2 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
12980000
CY2024Q2 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
5359000
CY2024Q2 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
7621000
CY2023Q4 us-gaap Capitalized Contract Cost Gross
CapitalizedContractCostGross
12980000
CY2023Q4 us-gaap Capitalized Contract Cost Accumulated Amortization
CapitalizedContractCostAccumulatedAmortization
5058000
CY2023Q4 us-gaap Capitalized Contract Cost Net
CapitalizedContractCostNet
7922000
CY2024Q2 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5620000
CY2024Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2320000
CY2024Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3300000
CY2023Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
5620000
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2190000
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3430000
CY2024Q2 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
200000
CY2023Q2 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
200000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
300000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
400000
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6603000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8544000
CY2024Q2 lqda Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1586000
CY2023Q4 lqda Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2902000
CY2024Q2 lqda Accrued Inventory Costs
AccruedInventoryCosts
2248000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2663000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1954000
CY2024Q2 lqda Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
13100000
CY2023Q4 lqda Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
13400000
CY2020Q4 lqda Share Based Compensation Arrangement By Share Based Payment Award Threshold Increase In Shares Available For Issuance As Percentage Of Stock Issued And Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuanceAsPercentageOfStockIssuedAndOutstanding
0.010
CY2020Q4 lqda Share Based Compensation Arrangement By Share Based Payment Award Threshold Increase In Shares Available For Issuance
ShareBasedCompensationArrangementByShareBasedPaymentAwardThresholdIncreaseInSharesAvailableForIssuance
150000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4372000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2499000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8896000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5051000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.84
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.09
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9573937
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
33933
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.85
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
139260
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.54
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9408244
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.80
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M6D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
67980000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6563332
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.52
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
49365000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9043468
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.76
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
65681000
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2024Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2024Q2 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.065
CY2024Q2 us-gaap Lease Cost
LeaseCost
219000
CY2023Q2 us-gaap Lease Cost
LeaseCost
221000
us-gaap Lease Cost
LeaseCost
437000
us-gaap Lease Cost
LeaseCost
451000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y3M18D
CY2024Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M18D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.103
CY2024Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.065
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
662000
CY2024Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
57000
CY2024Q2 lqda Lease Liability Payments Due Remainder Of Fiscal Year
LeaseLiabilityPaymentsDueRemainderOfFiscalYear
719000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1356000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
64000
CY2024Q2 lqda Lease Liability Payments Due Next Twelve Months
LeaseLiabilityPaymentsDueNextTwelveMonths
1420000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1158000
CY2024Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
0
CY2024Q2 lqda Lease Liability Payments Due Year Two
LeaseLiabilityPaymentsDueYearTwo
1158000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3176000
CY2024Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
121000
CY2024Q2 lqda Lease Liability Payments Due Total
LeaseLiabilityPaymentsDueTotal
3297000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
343000
CY2024Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
3000
CY2024Q2 lqda Lease Liability Undiscounted Excess Amount
LeaseLiabilityUndiscountedExcessAmount
346000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2833000
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
118000
CY2024Q2 lqda Lease Liability
LeaseLiability
2951000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-2300000
CY2024Q2 lqda Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
4200000
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-11500000
CY2023Q4 lqda Revenue Interest Financing Agreement
RevenueInterestFinancingAgreement
46033000
CY2024Q1 lqda Revenue Interest Financing Agreement Accretion
RevenueInterestFinancingAgreementAccretion
107000
CY2024Q1 lqda Revenue Interest Financing Agreement Amortization Of Debt Discount
RevenueInterestFinancingAgreementAmortizationOfDebtDiscount
2000
CY2024Q1 lqda Revenue Interest Financing Agreement Amount Funded Under Second Tranche
RevenueInterestFinancingAgreementAmountFundedUnderSecondTranche
24975000
CY2024Q1 lqda Revenue Interest Financing Agreement
RevenueInterestFinancingAgreement
71117000
CY2024Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
11483000
CY2024Q1 lqda Revenue Interest Financing Agreement
RevenueInterestFinancingAgreement
82600000
lqda Revenue Interest Financing Agreement Accretion
RevenueInterestFinancingAgreementAccretion
5010000
lqda Payments On Revenue Interest Financing Liability
PaymentsOnRevenueInterestFinancingLiability
1692000
CY2024Q2 lqda Revenue Interest Financing Agreement
RevenueInterestFinancingAgreement
85918000
CY2024Q2 lqda Revenue Interest Financing Payable Current
RevenueInterestFinancingPayableCurrent
4154000
CY2024Q2 lqda Revenue Interest Financing Payable Noncurrent
RevenueInterestFinancingPayableNoncurrent
81764000
lqda Schedule Of Expected Annual Payments On Revenue Interest Financing Agreement
ScheduleOfExpectedAnnualPaymentsOnRevenueInterestFinancingAgreement
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year ending December 31:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024 (six months remaining)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,077</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 37,507</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,214</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,214</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,214</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2029</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,553</p></td></tr><tr><td style="vertical-align:bottom;width:84.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 114,779</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p>
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Remainder Of Fiscal Year
RevenueInterestFinancingAgreementExpectedPaymentsRemainderOfFiscalYear
2077000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Year One
RevenueInterestFinancingAgreementExpectedPaymentsYearOne
37507000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Year Three
RevenueInterestFinancingAgreementExpectedPaymentsYearThree
23214000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Year Four
RevenueInterestFinancingAgreementExpectedPaymentsYearFour
23214000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Year Five
RevenueInterestFinancingAgreementExpectedPaymentsYearFive
23214000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Year Six
RevenueInterestFinancingAgreementExpectedPaymentsYearSix
5553000
CY2024Q2 lqda Revenue Interest Financing Agreement Expected Payments Total
RevenueInterestFinancingAgreementExpectedPaymentsTotal
114779000
CY2024Q2 lqda Non Cancelable Future Commitment For Product Manufacturing And Supply Costs
NonCancelableFutureCommitmentForProductManufacturingAndSupplyCosts
3500000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001558370-24-011206-index-headers.html Edgar Link pending
0001558370-24-011206-index.html Edgar Link pending
0001558370-24-011206.txt Edgar Link pending
0001558370-24-011206-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
lqda-20240630.xsd Edgar Link pending
lqda-20240630x10q.htm Edgar Link pending
lqda-20240630x10q002.jpg Edgar Link pending
lqda-20240630xex31d1.htm Edgar Link pending
lqda-20240630xex31d2.htm Edgar Link pending
lqda-20240630xex32d1.htm Edgar Link pending
lqda-20240630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
lqda-20240630_lab.xml Edgar Link unprocessable
lqda-20240630_pre.xml Edgar Link unprocessable
lqda-20240630_def.xml Edgar Link unprocessable
lqda-20240630x10q_htm.xml Edgar Link completed
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lqda-20240630_cal.xml Edgar Link unprocessable